{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:52:13Z","timestamp":1793465533712,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jdermsci.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T02:45:50Z","timestamp":1680230750000},"page":"19-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study"],"prefix":"10.1016","volume":"110","author":[{"given":"Takashi","family":"Inozume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Kiniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Mizuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamitsu","family":"Matsuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Isei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Uhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jdermsci.2023.03.008_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jdermsci.2023.03.008_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.jdermsci.2023.03.008_bib3","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jdermsci.2023.03.008_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of Nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jdermsci.2023.03.008_bib5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.jdermsci.2023.03.008_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100325","article-title":"Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)","volume":"6","author":"Nakamura","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jdermsci.2023.03.008_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.21241","article-title":"Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study","author":"Bai","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"15","key":"10.1016\/j.jdermsci.2023.03.008_bib8","article-title":"Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: a retrospective, multicenter study (JAMP-neo study)","volume":"39","author":"Nakamura","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7653","key":"10.1016\/j.jdermsci.2023.03.008_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jdermsci.2023.03.008_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jdermsci.2023.03.008_bib11","article-title":"Positive association between location of Melanoma, ultraviolet signature, tumor mutational burden, and response to anti-PD-1 therapy","volume":"5","author":"Dousset","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"2","key":"10.1016\/j.jdermsci.2023.03.008_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"issue":"16","key":"10.1016\/j.jdermsci.2023.03.008_bib13","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5786","key":"10.1016\/j.jdermsci.2023.03.008_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.1127515","article-title":"MC1R germline variants confer risk for BRAF-mutant melanoma","volume":"313","author":"Landi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jdermsci.2023.03.008_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.02.026","article-title":"Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study","volume":"167","author":"van Not","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jdermsci.2023.03.008_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.06.004","article-title":"Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study","author":"Dimitriou","year":"2022","journal-title":"Ann. Oncol."},{"issue":"6349","key":"10.1016\/j.jdermsci.2023.03.008_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jdermsci.2023.03.008_bib18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"8","key":"10.1016\/j.jdermsci.2023.03.008_bib19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.jdermsci.2023.03.008_bib20","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1172\/JCI121476","article-title":"Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma","volume":"128","author":"Smith","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jdermsci.2023.03.008_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jdermsci.2023.03.008_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jdermsci.2023.03.008_bib23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jdermsci.2023.03.008_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13073-019-0636-8","article-title":"Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma","volume":"11","author":"Loffler","year":"2019","journal-title":"Genome Med."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:52:43Z","timestamp":1760331163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181123000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0923181123000774"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.03.008","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}